top of page
  • Facebook
  • Twitter
  • Instagram
Sokolski Headshot_edited.jpg

Eleasa Sokolski, MD
Assistant Professor of Medicine and Psychiatry
Oregon Health & Science University

Treatment of Methamphetamine Use Disorder
Saturday, February 13, 2027
10:15 AM - 11:15 AM

Dr. Eleasa Sokolski is an Assistant Professor of Medicine and Psychiatry at Oregon Health & Science University. After graduating from UC San Diego School of Medicine, she completed a combined residency in internal medicine and psychiatry at UC Davis followed by an addiction medicine fellowship at OHSU. Her clinical work includes inpatient addiction medicine consultation at OHSU and Hillsboro Medical Center, and outpatient psychiatry consultation in the OHSU internal medicine clinic. 

​

In addition to her clinical work, Dr. Sokolski holds several roles in education leadership. She serves as the deputy director for the Oregon ECHO Network Addiction Medicine program, which provides state-wide education in the treatment of substance use disorders, and as the co-director of the Chief Resident and Fellow Addiction Medicine Champion Program (CHAMP), which empowers OHSU fellows and chiefs to become leaders in addiction medicine education. In her free time, she enjoys rock climbing, trail running, and spending time with her husband and two dogs.
 

Lecture Summary:

This presentation will review current evidence-based approaches to the treatment of methamphetamine use disorder, including both behavioral interventions and off-label pharmacotherapy. The session will examine the role of strategies such as contingency management and summarize available evidence for medications used in the absence of an FDA-approved pharmacologic treatment. The presentation will also address common neuropsychiatric complications associated with methamphetamine use and practical considerations for their clinical management.

​Goals and Learning Objectives:

  • Understand the role of behavioral interventions in treating methamphetamine use disorder, including contingency management.

  • Review the evidence for pharmacologic management of methamphetamine use disorder with off-label medications.

  • Learn to address neuropsychiatric toxicities associated with methamphetamine use.

​

Disclosures:

This speaker has no disclosures to provide.

bottom of page